{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:57:02Z","timestamp":1786719422084,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T00:00:00Z","timestamp":1719014400000},"content-version":"am","delay-in-days":295,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.radonc.2023.109742","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T20:55:32Z","timestamp":1686603332000},"page":"109742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-4616","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Vendrely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ronchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Minsat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Le Malicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lemanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mirabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Luc","family":"Etienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Li\u00e8vre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Darut-Jouve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"de la Fouchardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Breysacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Argo-Leignel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Thimonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Magn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meher Ben","family":"Abdelghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00f4me","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109742_b0005","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2023.109742_b0010","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"40","author":"Glynne-Jones","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0015","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.radonc.2023.109742_b0020","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/BF02238600","article-title":"Combined therapy for cancer of the anal canal: a preliminary report. 1974","volume":"36","author":"Nigro","year":"1993","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.radonc.2023.109742_b0025","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0030","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0035","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2023.109742_b0040","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2023.109742_b0045","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 Trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0050","first-page":"942","article-title":"Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification","volume":"19","author":"Alvarez","year":"2006","journal-title":"Mod Pathol Off J U S Can Acad Pathol Inc."},{"key":"10.1016\/j.radonc.2023.109742_b0055","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.humpath.2009.05.010","article-title":"Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus","volume":"40","author":"Walker","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.radonc.2023.109742_b0060","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1099\/jgv.0.001061","article-title":"E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line","volume":"99","author":"Wechsler","year":"2018","journal-title":"J Gen Virol"},{"key":"10.1016\/j.radonc.2023.109742_b0065","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0070","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.radonc.2015.02.008","article-title":"Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial","volume":"114","author":"Levy","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0075","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2016.69.1642","article-title":"Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial","volume":"35","author":"Sparano","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0080","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","article-title":"Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)","volume":"35","author":"Garg","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0085","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2018.01.007","article-title":"Treatment of squamous cell carcinoma of the anal canal: a new strategies with anti-EGFR therapy and immunotherapy","volume":"123","author":"Casadei Gardini","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2023.109742_b0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.radonc.2019.05.018","article-title":"Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904)","volume":"140","author":"Vendrely","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0095","unstructured":"ICRU. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). ICRU Report 83. J ICRU. 2010, p. 1\u201306."},{"key":"10.1016\/j.radonc.2023.109742_b0100","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.ejca.2015.08.029","article-title":"Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer","volume":"51","author":"Leon","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2023.109742_b0105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.radonc.2018.08.008","article-title":"Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: a pooled analysis of two prospective trials (KANAL 2 and ACCORD 03)","volume":"129","author":"Faivre","year":"2018","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2019.08.022","article-title":"Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)","volume":"1990","author":"Rivin Del Campo","year":"2019","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.radonc.2023.109742_b0120","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ijrobp.2010.07.1995","article-title":"\u201cMind the gap\u201d\u2013the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I)","volume":"81","author":"Glynne-Jones","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109742_b0125","doi-asserted-by":"crossref","first-page":"E164","DOI":"10.1016\/j.ijrobp.2016.06.1006","article-title":"The development of an umbrella trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus","volume":"96","author":"Sebag-Montefiore","year":"2016","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0130","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clon.2016.10.005","article-title":"Initial results from the royal college of radiologists\u2019 UK national audit of anal cancer radiotherapy 2015","volume":"29","author":"Muirhead","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0135","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.radonc.2021.12.050","article-title":"Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: a multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG)","volume":"167","author":"Martin","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0140","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cam4.2722","article-title":"VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09\u201302)","volume":"9","author":"Feliu","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2023.109742_b0145","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.4004","article-title":"Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP\/5FU in squamous cell carcinoma of the anus: results of ACT II","volume":"30","author":"Glynne-Jones","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0150","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109742_b0155","article-title":"Treatment, outcome, and prognostic factors in non-metastatic anal cancer: the French nationwide cohort study FFCD-ANABASE","volume":"21","author":"Vendrely","year":"2023","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023002803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023002803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:33Z","timestamp":1759123533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023002803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":31,"alternative-id":["S0167814023002803"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109742","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109742"}}